Cervical cancer - Overview and Epidemiology

Cervical Cancer: Definition and Epidemiology What is Cervical Cancer? Cervical cancer is a malignant tumor that develops in the cervix, which is the lower narrow portion of the uterus that connects to the vagina. The cancer arises when cells in this region undergo abnormal changes and begin to grow uncontrollably. These abnormal cells can invade deeper into the cervical tissue and, if left untreated, can spread to other organs in the body. Global Disease Burden Cervical cancer represents a significant global health burden. Worldwide, it is the fourth most common cancer overall and the fourth leading cause of cancer death in women. In 2022 alone, over 660,000 new cases were diagnosed and approximately 350,000 deaths occurred—accounting for roughly 8 percent of all cancer cases and cancer deaths among women globally. However, the burden is not equally distributed. A critical disparity exists between resource levels: approximately 90 percent of cervical cancer cases and deaths occur in low- and middle-income countries. This striking inequality is reflected in the cancer's proportion of overall female cancers: in high-income countries cervical cancer represents only about 2 percent of female cancers, whereas in low- and middle-income countries it accounts for 17 percent. The mortality disparities are even more dramatic when comparing individual countries. Mortality rates vary more than fifty-fold globally, ranging from less than 2 deaths per 100,000 women in some high-income countries to over 40 deaths per 100,000 in some sub-Saharan African countries. These massive differences reflect unequal access to screening and treatment services. Epidemiology in High-Income Countries North America In the United States, the median age at diagnosis is 50 years, and the incidence rate from 2018 to 2022 was 7.7 cases per 100,000 women. Perhaps more importantly, cervical cancer deaths in the United States declined by approximately 74 percent over the 50 years leading up to 2010—a remarkable achievement largely attributed to widespread adoption of Pap test screening programs. This dramatic mortality reduction demonstrates how screening technology can fundamentally transform cancer outcomes. Europe Similar success has been documented in Europe. Since organized screening programs began in 1991, the number of new cervical cancer diagnoses in European countries has declined on average by 4.5 percent each year between 1991 and 2005—showing the sustained impact of systematic screening. The Critical Role of Screening Programs The epidemiological data from high-income countries reveals a crucial pattern: organized screening programs are strongly associated with substantial declines in both cervical cancer incidence and mortality. This relationship is fundamental to understanding cervical cancer epidemiology. When screening programs are established and widely implemented, they detect precancerous and early-stage cancerous lesions before they progress to advanced disease. This early detection allows for more effective treatment and prevents progression to life-threatening cancer. In contrast, regions without organized screening programs experience higher incidence and mortality rates because cancers are detected at later stages when they are more difficult to treat. This explains the stark regional disparities noted earlier: high-income regions, which have robust screening infrastructure, show substantially lower incidence and mortality compared with low- and middle-income regions, which often lack these critical public health programs. <extrainfo> Additional Monitoring Data Registry and monitoring programs, such as the National Cervical Screening Program in Australia, continue to track screening outcomes and help countries evaluate the effectiveness of their cervical cancer prevention strategies. </extrainfo>